Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Our collaboration with Daiichi Sankyo is an exciting opportunity to unlock therapeutic access to new cell types, paving the way for precision treatments that can transform patient outcomes.” ...

--(BUSINESS WIRE)--#RNA--Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today announced it entered into a Research Collaboration and ...

J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target of Yen4,600.00. The company’s shares closed ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Wildfires damaged 16,000 structures Munich Re's Q4 net profit falls 2.5%, misses expectations Expects 6 billion euro profit in 2025 FRANKFURT, Feb 26 - Germany's Munich Re (MUVGn.DE), opens new ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Munich Re on Wednesday stood by its profit target for 2025 and raised its dividend by a third, despite ...

Most flight connections at Munich Airport are set to be canceled on Thursday and Friday due to a strike by airport workers, the airport announced on Tuesday. Airport authorities said the airlines ...

Public sector workers and ground staff at Munich Airport are set to launch a two-day strike starting Thursday after wage negotiations ended without result, the Verdi trade union said on Monday, ...